-
Je něco špatně v tomto záznamu ?
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients
A. Jurczyszyn, J. Radocha, J. Davila, MA. Fiala, A. Gozzetti, N. Grząśko, P. Robak, I. Hus, A. Waszczuk-Gajda, R. Guzicka-Kazimierczak, E. Atilla, G. Mele, W. Sawicki, DS. Jayabalan, G. Charliński, AG. Szabo, R. Hajek, M. Delforge, A. Kopacz, D....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie
PubMed
29315478
DOI
10.1111/bjh.15092
Knihovny.cz E-zdroje
- MeSH
- autologní štěp MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- plazmocelulární leukemie mortalita patologie terapie MeSH
- přežití bez známek nemoci MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- transplantace kmenových buněk * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
We report a multicentre retrospective study that analysed clinical characteristics and outcomes in 117 patients with primary plasma cell leukaemia (pPCL) treated at the participating institutions between January 2006 and December 2016. The median age at the time of pPCL diagnosis was 61 years. Ninety-eight patients were treated with novel agents, with an overall response rate of 78%. Fifty-five patients (64%) patients underwent upfront autologous stem cell transplantation (ASCT). The median follow-up time was 50 months (95% confidence interval [CI] 33; 76), with a median overall survival (OS) for the entire group of 23 months (95% CI 15; 34). The median OS time in patients who underwent upfront ASCT was 35 months (95% CI 24·3; 46) as compared to 13 months (95% CI 6·3; 35·8) in patients who did not receive ASCT (P = 0·001). Multivariate analyses identified age ≥60 years, platelet count ≤100 × 109 /l and peripheral blood plasma cell count ≥20 × 109 /l as independent predictors of worse survival. The median OS in patients with 0, 1 or 2-3 of these risk factors was 46, 27 and 12 months, respectively (P < 0·001). Our findings support the use of novel agents and ASCT as frontline treatment in patients with pPCL. The constructed prognostic score should be independently validated.
Dana Farber Cancer Institute Harvard Medical School Boston MA USA
Department of Haematology and Bone Marrow Transplantation Medical University of Lublin Lublin Poland
Department of Haematology Medical University of Lodz Copernicus Memorial Hospital Łódź Poland
Department of Haematology Nicolaus Copernicus Hospital Torun Poland
Department of Haematology Oncology and Internal Medicine Warsaw Medical University Warsaw Poland
Department of Haematology Pomeranian Medical University Szczecin Poland
Department of Haematology State Hospital Cracow Poland
Department of Haematology State Hospital Opole Poland
Department of Haematology University of Rzeszów Rzeszów Poland
Department of Haematology UZ Leuven Leuven Belgium
Department of Medicine Section of Haematology Vejle Denmark
Dept of Internal Medicine and Haematology Military Institute of Medicine Warsaw Poland
Hospital Universitario de Salamanca Salamanca Spain
Jagiellonian University Medical College Cracow Poland
John Theurer Cancer Center at Hackensack University Medical Center Hackensack NJ USA
Le Scotte Hospital Siena Italy
Maria Sklodowska Curie Institute Oncology Centre Warsaw Poland
Massachusetts General Hospital Cancer Center Harvard Medical School Boston MA USA
Ministry of Interior Hospital in Olsztyn with Warmia and Masuria Oncology Centre Olsztyn Poland
Norwegian University of Science and Technology Trondheim Norway
Ospedale A Perrino Haemetaology Brindisi Italy
Rutgers New Jersey Medical School Newark NJ USA
Seccion Hematologia Adultos Hospital Italiano de Buenos Aires Buenos Aires Argentina
Service d'Hematologie CHU Hopital de la Miletrie Poitiers France
Tel Aviv Medical Centre Tel Aviv Israel
University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012937
- 003
- CZ-PrNML
- 005
- 20190411093916.0
- 007
- ta
- 008
- 190405s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bjh.15092 $2 doi
- 035 __
- $a (PubMed)29315478
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Jurczyszyn, Artur $u Jagiellonian University Medical College, Cracow, Poland.
- 245 10
- $a Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients / $c A. Jurczyszyn, J. Radocha, J. Davila, MA. Fiala, A. Gozzetti, N. Grząśko, P. Robak, I. Hus, A. Waszczuk-Gajda, R. Guzicka-Kazimierczak, E. Atilla, G. Mele, W. Sawicki, DS. Jayabalan, G. Charliński, AG. Szabo, R. Hajek, M. Delforge, A. Kopacz, D. Fantl, A. Waage, I. Avivi, M. Rodzaj, X. Leleu, V. Richez, W. Knopińska-Posłuszny, A. Masternak, AJ. Yee, A. Barchnicka, A. Druzd-Sitek, T. Guerrero-Garcia, J. Liu, DH. Vesole, JJ. Castillo,
- 520 9_
- $a We report a multicentre retrospective study that analysed clinical characteristics and outcomes in 117 patients with primary plasma cell leukaemia (pPCL) treated at the participating institutions between January 2006 and December 2016. The median age at the time of pPCL diagnosis was 61 years. Ninety-eight patients were treated with novel agents, with an overall response rate of 78%. Fifty-five patients (64%) patients underwent upfront autologous stem cell transplantation (ASCT). The median follow-up time was 50 months (95% confidence interval [CI] 33; 76), with a median overall survival (OS) for the entire group of 23 months (95% CI 15; 34). The median OS time in patients who underwent upfront ASCT was 35 months (95% CI 24·3; 46) as compared to 13 months (95% CI 6·3; 35·8) in patients who did not receive ASCT (P = 0·001). Multivariate analyses identified age ≥60 years, platelet count ≤100 × 109 /l and peripheral blood plasma cell count ≥20 × 109 /l as independent predictors of worse survival. The median OS in patients with 0, 1 or 2-3 of these risk factors was 46, 27 and 12 months, respectively (P < 0·001). Our findings support the use of novel agents and ASCT as frontline treatment in patients with pPCL. The constructed prognostic score should be independently validated.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a autologní štěp $7 D064592
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a plazmocelulární leukemie $x mortalita $x patologie $x terapie $7 D007952
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a transplantace kmenových buněk $7 D033581
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Radocha, Jakub $u 4th Department of Medicine - Haematology, Charles University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
- 700 1_
- $a Davila, Julio $u Hospital Universitario de Salamanca, Salamanca, Spain.
- 700 1_
- $a Fiala, Mark A $u Washington University School of Medicine, Saint Louis, MO, USA.
- 700 1_
- $a Gozzetti, Alessandro $u Le Scotte Hospital, Siena, Italy.
- 700 1_
- $a Grząśko, Norbert $u Department of Haematology, St John's Cancer Centre, Lublin, Poland. Department of Experimental Haematology, Medical University of Lublin, Lublin, Poland.
- 700 1_
- $a Robak, Paweł $u Department of Haematology, Medical University of Lodz, Copernicus Memorial Hospital, Łódź, Poland.
- 700 1_
- $a Hus, Iwona $u Department of Haematology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
- 700 1_
- $a Waszczuk-Gajda, Anna $u Department of Haematology, Oncology and Internal Medicine, Warsaw Medical University, Warsaw, Poland.
- 700 1_
- $a Guzicka-Kazimierczak, Renata $u Department of Haematology, Pomeranian Medical University, Szczecin, Poland.
- 700 1_
- $a Atilla, Erden $u Haematology Department and Bone Marrow Transplantation Unit, Ankara University Medical School, Ankara, Turkey.
- 700 1_
- $a Mele, Giuseppe $u Ospedale A. Perrino, Haemetaology, Brindisi, Italy.
- 700 1_
- $a Sawicki, Waldemar $u Dept. of Internal Medicine and Haematology, Military Institute of Medicine, Warsaw, Poland.
- 700 1_
- $a Jayabalan, David S $u Weill Cornell Medical College, New York, NY, USA.
- 700 1_
- $a Charliński, Grzegorz $u Department of Haematology, Nicolaus Copernicus Hospital, Torun, Poland.
- 700 1_
- $a Szabo, Agoston G $u Department of Medicine, Section of Haematology, Vejle, Denmark.
- 700 1_
- $a Hajek, Roman $u University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Delforge, Michel $u Department of Haematology, UZ Leuven, Leuven, Belgium.
- 700 1_
- $a Kopacz, Agnieszka $u Department of Haematology, University of Rzeszów, Rzeszów, Poland.
- 700 1_
- $a Fantl, Dorotea $u Seccion Hematologia Adultos, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
- 700 1_
- $a Waage, Anders $u Norwegian University of Science and Technology, Trondheim, Norway.
- 700 1_
- $a Avivi, Irit $u Tel Aviv Medical Centre, Tel Aviv, Israel.
- 700 1_
- $a Rodzaj, Marek $u Department of Haematology, State Hospital, Cracow, Poland.
- 700 1_
- $a Leleu, Xavier $u Service d'Hematologie CHU, Hopital de la Miletrie, Poitiers, France.
- 700 1_
- $a Richez, Valentine $u Ministry of Interior Hospital in Olsztyn with Warmia and Masuria Oncology Centre, Olsztyn, Poland.
- 700 1_
- $a Knopińska-Posłuszny, Wanda $u Ministry of Interior Hospital in Olsztyn with Warmia and Masuria Oncology Centre, Olsztyn, Poland.
- 700 1_
- $a Masternak, Anna $u Department of Haematology, State Hospital, Opole, Poland.
- 700 1_
- $a Yee, Andrew J $u Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
- 700 1_
- $a Barchnicka, Agnieszka $u Department of Doctoral Studies, School of Public Health in Bytom, Medical University of Silesia, Katowice, Poland.
- 700 1_
- $a Druzd-Sitek, Agnieszka $u Maria Sklodowska-Curie Institute - Oncology Centre, Warsaw, Poland.
- 700 1_
- $a Guerrero-Garcia, Thomas $u Division of Hematology and Oncology, Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton, MA, USA.
- 700 1_
- $a Liu, Jieqi $u Rutgers New Jersey Medical School, Newark, NJ, USA.
- 700 1_
- $a Vesole, David H $u John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
- 700 1_
- $a Castillo, Jorge J $u Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
- 773 0_
- $w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 180, č. 6 (2018), s. 831-839
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29315478 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190411093933 $b ABA008
- 999 __
- $a ok $b bmc $g 1392247 $s 1051242
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 180 $c 6 $d 831-839 $e 20180107 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
- LZP __
- $a Pubmed-20190405
